StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

Earnings

Candel Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.28
-$0.21 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Candel Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026after the close––-$0.28Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026before the open––-$0.52Release
Q1 FY2026ended Mar 31, 2026May 14, 2026before the open––-$0.14Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026before the open––-$0.54Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025before the open––-$0.21Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025before the open–––Release
Q1 FY2025ended Mar 31, 2025May 13, 2025before the open––$0.13Release
Q4 FY2024ended Dec 31, 2024Mar 13, 2025after the close––-$0.40Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024before the open––-$0.74Release
Q1 FY2024ended Mar 31, 2024May 14, 2024before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Candel Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Candel Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Candel Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Update
  6. Update
  7. Results
  8. Results
  9. News
  10. News
  11. Results
  12. Update
  13. Results
  14. Results
  15. Results

See a number that looks wrong?